2% Topical Minoxidil Solution in Male-Pattern Baldness: Preliminary European Results

Civatte, J; Laux, Barbara; Simpson, N. B.; Vickers, C. F. H.

doi:10.1159/000248902

Cited by 21 publications

(11 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparable to the results in total hair count the mean changes in nonvellus hair counts were also significantly different to placebo (p between < 0.05 and 0.001). There was a mean change in nonvellus hair counts between 4.7 hairs/cm 2 to 37.3 hairs/cm 2 (17.2–59.4 %) at 6 months, between 9.4 hairs/cm 2 to 41.8 hairs/cm 2 (8.8–443.8 %) at 12 months [12, 13, 17–22, 24, 26, 27, 29, 30, 33, 35, 43, 45].…”

Section: Therapeutic Options and Therapy Assessmentmentioning

confidence: 99%

Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men

Blumeyer

Tosti

Messenger

et al. 2011

J Deutsche Derma Gesell

246

223

View full text Add to dashboard Cite

SummaryAndrogenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80 % Caucasian men and 42 % of women. Patients diagnosed with androgenetic alopecia may undergo significant impairment of quality of life. Despite the high prevalence and the variety of therapeutic options available, there have been no national or international evidencebased guidelines for the treatment of androgenetic alopecia in men and women so far. Therefore, the European Dermatology Forum (EDF) initiated a project to develop an evidence-based S3 guideline for the treatment of androgenetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists as well as general practitioners with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia. Keywords• alopecia • androgenetic • Therapy • Guideline • hair loss I Introduction to the guideline Needs/problems and issues in patient careAndrogenetic alopecia (AGA) is a common chronic dermatologic disease, affecting both men and women. It is characterized by progressive hair loss usually occurring in a pattern distribution. The frequency increases with age. In Caucasians, at the age of 70 or beyond 80 % of men and up to 42 % of women have signs of androgenetic alopecia. Though the prevalence is high in elderly patients, androgenetic alopecia often already starts at puberty.Independent of age and gender, patients diagnosed with androgenetic alopecia undergo significant impairment in their quality of life. Hair is an important feature of image. Hair loss affects self-esteem, personal attractiveness and may lead to depression and other negative effects of life [1]. Androgenetic alopecia is clearly a burden for both sexes, but it is substantially more distressing for women [2].

show abstract

Section: Therapeutic Options and Therapy Assessmentmentioning

confidence: 99%

Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men

Blumeyer

Tosti

Messenger

et al. 2011

J Deutsche Derma Gesell

246

223

View full text Add to dashboard Cite

show abstract

“…Minoxidil 5% topical solution (5% MTS) and 5% minoxidil topical foam (5% MTF) twice daily are both approved therapies for AGA in the vertex region in men [2,3,4,5,6]. …”

Section: Introductionmentioning

confidence: 99%

A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men

Hillmann

Bartels

Kottner

et al. 2015

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Background: 5% minoxidil formulations twice daily are effective in treating vertex male androgenetic alopecia (AGA); however, efficacy and safety data in frontotemporal regions are lacking. Objectives: To assess the efficacy of 5% minoxidil topical foam (5% MTF) in the frontotemporal region of male AGA patients after 24 weeks of treatment compared to placebo treatment and to the vertex region. Methods: Seventy males with moderate AGA applied 5% MTF or placebo foam (plaTF) twice daily for 24 weeks in frontotemporal and vertex regions. Target area non-vellus hair count (TAHC) was the primary end point. Results: Frontotemporal and vertex TAHC and target area cumulative non-vellus hair width (TAHW) showed similar responses to 5% MTF with significant increases up to week 16 compared to baseline (p < 0.001). After 24 weeks of treatment, frontotemporal TAHW increased significantly in the 5% MTF group compared to the plaTF group (p = 0.017), while TAHC showed a similar non-significant increase from baseline in both regions. At 24 weeks, 5% MTF users rated a significant improvement in scalp coverage for the frontotemporal (p = 0.016) and vertex areas (p = 0.027). Conclusions: 5% MTF twice a day promotes hair density and width in both frontotemporal and vertex regions in men with moderate stages of AGA.

show abstract

“…). Seventy‐eight, met the inclusion criteria and were included in the quantitative analysis. A total of 15 888 participants (88.1% male) were included with an average age 36.0 ± 7.3 (Table ).…”

Section: Resultsmentioning

confidence: 99%

Efficacy of non‐surgical treatments for androgenetic alopecia: a systematic review and network meta‐analysis

Gupta

Mays

Dotzert

et al. 2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

Androgenetic alopecia, or male/female pattern baldness, is the most common type of progressive hair loss disorder. The aim of this study was to review recent advances in non-surgical treatments for androgenetic alopecia and identify the most effective treatments. A network meta-analysis (NMA) was conducted of the available literature of the six most common non-surgical treatment options for treating androgenetic alopecia in both men and women; dutasteride 0.5 mg, finasteride 1 mg, low-level laser therapy (LLLT), minoxidil 2%, minoxidil 5% and platelet-rich plasma (PRP). Seventy-eight studies met the inclusion criteria, and 22 studies had the data necessary for a network meta-analysis. Relative effects show LLLT as the superior treatment. Relative effects show PRP, finasteride 1 mg (male), finasteride 1 mg (female), minoxidil 5%, minoxidil 2% and dutasteride (male) are approximately equivalent in mean change hair count following treatment. Minoxidil 5% and minoxidil 2% reported the most drug-related adverse events (n = 45 and n = 23, respectively). The quality of evidence of minoxidil 2% vs. minoxidil 5% was high; minoxidil 5% vs. placebo was moderate; dutasteride (male) vs. placebo, finasteride (female) vs. placebo, minoxidil 2% vs. placebo and minoxidil 5% vs. LLLT was low; and finasteride (male) vs. placebo, LLLT vs. sham, PRP vs. placebo and finasteride vs. minoxidil 2% was very low. Results of this NMA indicate the emergence of novel, non-hormonal therapies as effective treatments for hair loss; however, the quality of evidence is generally low. High-quality randomized controlled trials and head-to-head trials are required to support these findings and aid in the development of more standardized protocols, particularly for PRP. Regardless, this analysis may aid physicians in clinical decision-making and highlight the variety of non-surgical hair restoration options for patients.

show abstract

2% Topical Minoxidil Solution in Male-Pattern Baldness: Preliminary European Results

Cited by 21 publications

References 1 publication

Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men

Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men

A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men

Efficacy of non‐surgical treatments for androgenetic alopecia: a systematic review and network meta‐analysis

Contact Info

Product

Resources

About